Agilent Q2 Beats Guidance as Revenue and Margins Rebound

What happened

Agilent reported Q2 fiscal 2026 revenue of $1.83B, up 10% reported and 6.3% core, exceeding the $1.79B-$1.82B guidance range. Non-GAAP EPS of $1.49 also topped the $1.39-$1.42 guide, with GAAP net income of $339M ($1.20 per share) up from $215M a year ago. The strong top-line growth and margin improvement (operating margin recovered to ~23% from 19.7% in Q1) suggest the Q1 margin compression driven by tariffs and mix was indeed transitory. Management's ability to deliver on its explicit Q2 targets validates the demand recovery thesis and order conversion narrative. However, sustaining this margin trajectory through the second half of FY2026 and confirming that China stimulus materializes remain key uncertainties.

Implication

Q2 results reduce thesis risk but do not eliminate it. Investors should monitor Q3 guidance and margin sustainability; a trim above $135 remains prudent until multiple quarters confirm margin recovery. The 8-quarter book-to-bill streak and Q2 beat support a 55% base-case probability, but China and tariff headwinds warrant caution.

Thesis delta

The Q2 beat changes the narrative from 'growth without earnings quality' to 'recovery on track with margin re-expansion.' The prior thesis that next quarter operating margin must improve YoY has now been met, shifting the risk-reward slightly positive. However, the need to see consistent delivery over the next 1-2 quarters remains; the thesis evolves from 'wait and verify' to 'monitor for sustained margin improvement.'